| Dry Eye Syndromes
Lacrisert vs Tyrvaya
Side-by-side clinical, coverage, and cost comparison for dry eye syndromes.Deep comparison between: Lacrisert vs Tyrvaya with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTyrvaya has a higher rate of injection site reactions vs Lacrisert based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tyrvaya but not Lacrisert, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lacrisert
Tyrvaya
At A Glance
Ophthalmic insert
Once daily
Ocular lubricant
Nasal spray
Twice daily
Nicotinic acetylcholine receptor agonist
Indications
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- Exposure keratoconjunctivitis
- Corneal hypoesthesia
- Recurrent erosion of cornea
- Dry Eye Syndromes
Dosing
Dry Eye Syndromes, Keratoconjunctivitis Sicca, Exposure keratoconjunctivitis, Corneal hypoesthesia, Recurrent erosion of cornea One ophthalmic insert in each eye once daily; some patients may require twice daily use for optimal results; insert into the inferior cul-de-sac of the eye beneath the base of the tarsus.
Dry Eye Syndromes One spray in each nostril twice daily, approximately 12 hours apart; prime with 7 actuations before initial use and re-prime with 1 actuation if not used for more than 5 days.
Contraindications
- Hypersensitivity to hydroxypropyl cellulose
—
Adverse Reactions
Most common Transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, edema of the eyelids, hyperemia
Most common (>=5%) sneezing (82%), cough (16%), throat irritation (13%), instillation-site (nose) irritation (8%)
Pharmacology
Ocular lubricant; stabilizes and thickens the precorneal tear film and prolongs tear film breakup time to reduce signs and symptoms of dry eye syndromes, including lubrication and protection of the eye.
Nicotinic acetylcholine receptor agonist; varenicline binds heteromeric nACh receptor subtypes (alpha4beta2, alpha4alpha6beta2, alpha3beta4, alpha3alpha5beta4) and the alpha7 receptor, activating the trigeminal parasympathetic pathway to increase basal tear film production in dry eye disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lacrisert
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Tyrvaya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Lacrisert
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tyrvaya
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (6/8)
Humana
Lacrisert
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Tyrvaya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lacrisert.
No savings programs available for Tyrvaya.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LacrisertView full Lacrisert profile
TyrvayaView full Tyrvaya profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.